share_log

10-K: FY2023 Annual Report

10-K: FY2023 Annual Report

10-K：2023財年年報
美股SEC公告 ·  04/16 17:31

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals, a pharmaceutical company, reported a net loss of $0.5 million for the year ended December 31, 2023, compared to a net loss of $4.9 million in the previous year. The company also experienced an increase in cash used in operating activities, reporting $7.7 million in 2023, up from $2.3 million in 2022. Despite completing a merger and a private placement totaling $20.0 million, Conduit Pharmaceuticals ended the year with an accumulated deficit of $11.3 million and acknowledged substantial doubt about its ability to continue as a going concern. The company's future plans include seeking additional funding through equity or debt financings to support its business plan. Conduit Pharmaceuticals is subject to industry risks such as regulatory approvals and dependence on key products and customers. The company's financial statements have been prepared under the assumption that it will continue as a going concern, without adjustments that might be necessary if the company is unable to continue in operation.
Conduit Pharmaceuticals, a pharmaceutical company, reported a net loss of $0.5 million for the year ended December 31, 2023, compared to a net loss of $4.9 million in the previous year. The company also experienced an increase in cash used in operating activities, reporting $7.7 million in 2023, up from $2.3 million in 2022. Despite completing a merger and a private placement totaling $20.0 million, Conduit Pharmaceuticals ended the year with an accumulated deficit of $11.3 million and acknowledged substantial doubt about its ability to continue as a going concern. The company's future plans include seeking additional funding through equity or debt financings to support its business plan. Conduit Pharmaceuticals is subject to industry risks such as regulatory approvals and dependence on key products and customers. The company's financial statements have been prepared under the assumption that it will continue as a going concern, without adjustments that might be necessary if the company is unable to continue in operation.
一家名爲Conduit Pharmaceuticals的藥品公司報告稱，在截至2023年12月31日的一年中，淨虧損爲50萬美元，相比上一年的淨虧損490萬美元有所減少。該公司在運營活動上的現金使用量也有所增加，2023年爲770萬美元，而2022年爲230萬美元。儘管完成了一次2000萬美元的合併和定向增發，Conduit Pharmaceuticals仍以1130萬美元的累計虧損結束了這一年，並承認其作爲繼續經營存在重大疑慮。該公司未來計劃通過股權或債務融資尋求額外資金來支持其業務計劃。Conduit Pharmaceuticals面臨着諸如監管批准和依賴於關鍵產品和客戶等行業風險。該公司的財務報表是在假定其將繼續經營的情況下編制的，而不考慮公司無法繼續經營時可能需要進行的調整。
一家名爲Conduit Pharmaceuticals的藥品公司報告稱，在截至2023年12月31日的一年中，淨虧損爲50萬美元，相比上一年的淨虧損490萬美元有所減少。該公司在運營活動上的現金使用量也有所增加，2023年爲770萬美元，而2022年爲230萬美元。儘管完成了一次2000萬美元的合併和定向增發，Conduit Pharmaceuticals仍以1130萬美元的累計虧損結束了這一年，並承認其作爲繼續經營存在重大疑慮。該公司未來計劃通過股權或債務融資尋求額外資金來支持其業務計劃。Conduit Pharmaceuticals面臨着諸如監管批准和依賴於關鍵產品和客戶等行業風險。該公司的財務報表是在假定其將繼續經營的情況下編制的，而不考慮公司無法繼續經營時可能需要進行的調整。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間